SCHEMBL25185136

SCHEMBL25185136

O=CC=CCN1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16654105 0.95 TRPA1 (0.36)
SCHEMBL20893392 0.95 TRPA1 (0.36)
SCHEMBL18306306 0.93 SMN1; SMN2 (0.39)
SCHEMBL28207021 0.93 SMN1; SMN2 (0.39)
SCHEMBL30623053 0.79 TRPA1 (0.37)
SCHEMBL19375823 0.79 KDM4E (0.41)
SCHEMBL20327298 0.78 KMT2A (0.34)
SCHEMBL30285988 0.76 ALOX15 (0.52)
SCHEMBL12955382 0.75 ALDH1A1 (0.38)
SCHEMBL21207694 0.73 SIGMAR1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118103370-A Fused tetracyclic quinazoline derivatives as ERBB2 inhibitors 英莱汶公司 2024-05-28 CN disclosed
WO-2023077259-A1 FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2023-05-11 WO disclosed